Congress Is Exploring Whether Medicare Can Incentivize Domestic Drug Manufacturing

Pharmaceutical manufacturing has traditionally been influenced by trade policy, tax incentives, and government investment. A new bipartisan Senate proposal suggests Congress is considering another lever: whether Medicare reimbursement could help encourage domestic drug manufacturing.

Legislation introduced by Sens. Adam Schiff, Democrat of California, and Rick Scott, Republican of Florida, would direct the Centers for Medicare and Medicaid Services to examine how its drug coverage and reimbursement authorities could reduce U.S. reliance on foreign pharmaceutical manufacturers. CMS would report its findings to Congress and could recommend reimbursement approaches that support domestic production of active pharmaceutical ingredients, key starting materials, and other critical pharmaceutical inputs.

The bill does not change Medicare payment policy. Instead, it asks whether Medicare's purchasing power could become part of a broader strategy to strengthen the pharmaceutical supply chain.

That question is significant.

For decades, manufacturing policy has largely been shaped through trade measures, grants, and tax incentives. This proposal introduces the possibility that healthcare reimbursement could also influence where pharmaceutical products are manufactured. If reimbursement eventually recognizes domestic production or supply chain resilience, manufacturing decisions could carry implications beyond cost and operational efficiency.

The proposal also reflects a broader policy trend. Governments are increasingly treating pharmaceutical manufacturing as strategic infrastructure rather than simply a commercial activity. The European Union's Critical Medicines Act pursues similar objectives through different policy mechanisms, highlighting a growing international focus on supply chain resilience.

Whether or not this legislation advances, it reflects a broader shift in policymaking. Manufacturing strategy is no longer being shaped solely by operations, trade, and tax policy. Congress is beginning to explore whether healthcare reimbursement should become part of that equation as well.

For pharmaceutical companies, the legislation is less important than the question it asks. If reimbursement policy eventually becomes another tool for strengthening domestic manufacturing, market strategy, capital planning, and manufacturing decisions may become more closely connected than they have been in the past.

At Lanton Strategies International, these are the kinds of intersections we focus on: where reimbursement, trade policy, industrial strategy, and commercial decision making begin to shape one another.

LSI Insight: This article reflects the independent analysis of Lanton Strategies International regarding emerging policy developments and their potential implications for healthcare, life sciences, and health technology organizations. It is intended for informational purposes only and should not be construed as legal, regulatory, or policy advice.